An effective method for the development of the liposomal nanoformulations  of docetaxel

Angham M. Abed; Majed K. Abbas; Amjed M. Oda

doi:10.53730/ijhs.v6nS2.5149

Authors

Angham M. Abed
anghammohsen89@gmail.com
University of Babylon, College of Medicine, Department of Pharmacology / Iraq
Majed K. Abbas University of Babylon, College of Medicine, Department of Pharmacology / Iraq
Amjed M. Oda University of Babylon / College of Basic Education, Department of chemistry, Iraq

Keywords:

prostate cancer, nanotechnology, drug delivery system, liposome, docetaxel

Abstract

Docetaxel has been regarded as among the most effective chemotherapeutic medications in recent decades, but its low solubility in water with systemic toxicities have made it difficult to use in clinical trials. Nanotechnology has supplied docetaxel with innovative drug delivery technologies in recent decades, allowing it to increase their water solubility and lessen adverse effects. Liposome was successfully used for encapsulation the Docetaxel in variant conditions and optimized to synthesis lecithin liposome and loaded one. The thin film hydration method was demonstrated for nanocapsules. The synthesized Docetaxel-liposome formula was investigated by SEM, TEM and zeta potential used for liposome stability. Encapsulation and loading efficiency was determined and releasing kinetics was studied at pH= 5.5 and 7. The kinetics models were studied included: zero-order, first-order order, Higuchi, and Korsmeyer Peppas model. The docetaxel-liposome was examined for its activity to kill prostate cancer in the cell line method and compared to free docetaxel (pure sample) and pharmaceutical formula. Our formula was very effective against prostate cancer and statistically significance.

Downloads

Download data is not yet available.

References

F. Odeh et al., “Co-encapsulation of thymoquinone with docetaxel enhances the encapsulation efficiency into PEGylated liposomes and the chemosensitivity of MCF7 breast cancer cells to docetaxel,” Heliyon, vol. 5, no. 11, p. e02919, 2019, doi: 10.1016/j.heliyon.2019.e02919.

R. Baghban et al., “Tumor microenvironment complexity and therapeutic implications at a glance,” Cell Commun. Signal., vol. 18, no. 1, pp. 1–19, 2020, doi: 10.1186/s12964-020-0530-4.

M. S. K. Albermani, H. J. Hammod, A. H. A. Kelkawi, and S. J. Alherby, “In-vitro study of layer double hydroxide nanoparticles as effective carrier to fight breast cancer growth,” J. Glob. Pharma Technol., vol. 10, no. 3, pp. 220–224, 2021.

G. Bozzuto and A. Molinari, “Liposomes as nanomedical devices,” Int. J. Nanomedicine, vol. 10, pp. 975–999, 2015, doi: 10.2147/IJN.S68861.

G. Sáez-Calvo et al., “Triazolopyrimidines Are Microtubule-Stabilizing Agents that Bind the Vinca Inhibitor Site of Tubulin,” Cell Chem. Biol., vol. 24, no. 6, pp. 737-750.e6, 2017, doi: 10.1016/j.chembiol.2017.05.016.

S. A. A. Razak et al., “Advances in nanocarriers for effective delivery of docetaxel in the treatment of lung cancer: An overview,” Cancers (Basel)., vol. 13, no. 3, pp. 1–25, 2021, doi: 10.3390/cancers13030400.

A. Loiseau et al., “Titanate nanotubes engineered with gold nanoparticles and docetaxel to enhance radiotherapy on xenografted prostate tumors,” Cancers (Basel)., vol. 11, no. 12, 2019, doi: 10.3390/cancers11121962.

R. Vakili-Ghartavol, S. M. Rezayat, R. Faridi-Majidi, K. Sadri, and M. R. Jaafari, “Optimization of Docetaxel Loading Conditions in Liposomes: proposing potential products for metastatic breast carcinoma chemotherapy,” Sci. Rep., vol. 10, no. 1, pp. 1–14, 2020, doi: 10.1038/s41598-020-62501-1.

G. Pauli, W. L. Tang, and S. D. Li, “Development and characterization of the solvent-assisted active loading technology (SALT) for liposomal loading of poorly water-soluble compounds,” Pharmaceutics, vol. 11, no. 9, 2019, doi: 10.3390/pharmaceutics11090465.

H. Zhang, “Thin-film hydration followed by extrusion method for liposome preparation,” Methods Mol. Biol., vol. 1522, pp. 17–22, 2017, doi: 10.1007/978-1-4939-6591-5_2.

A. Yousefi, F. Esmaeili, S. Rahimian, F. Atyabi, and R. Dinarvand, “Preparation and in vitro evaluation of a pegylated nano-liposomal formulation containing docetaxel,” Sci. Pharm., vol. 77, no. 2, pp. 453–464, 2009, doi: 10.3797/scipharm.0806-08.

E. Joseph and G. Singhvi, Multifunctional nanocrystals for cancer therapy: A potential nanocarrier. Elsevier Inc., 2019.

A. J. Shnoudeh et al., Synthesis, Characterization, and Applications of Metal Nanoparticles. Elsevier Inc., 2019.

S. Samimi, N. Maghsoudnia, R. B. Eftekhari, and F. Dorkoosh, Lipid-Based Nanoparticles for Drug Delivery Systems. Elsevier Inc., 2018.

I. M. Mahbubul, Stability and Dispersion Characterization of Nanofluid. 2019.

M. Sarfraz et al., “Liposomal co-delivered oleanolic acid attenuates doxorubicininduced multi-organ toxicity in hepatocellular carcinoma,” Oncotarget, vol. 8, no. 29, pp. 47136–47153, 2017, doi: 10.18632/oncotarget.17559.

M. C. O. Da Rocha et al., “Docetaxel-loaded solid lipid nanoparticles prevent tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells,” J. Nanobiotechnology, vol. 18, no. 1, pp. 1–20, 2020, doi: 10.1186/s12951-020-00604-7.

J. O. Eloy et al., “EGFR-targeted immunoliposomes efficiently deliver docetaxel to prostate cancer cells,” Colloids Surfaces B Biointerfaces, vol. 194, no. May, 2020, doi: 10.1016/j.colsurfb.2020.111185.

T. H. Tran et al., “Tumor-targeting, pH-sensitive nanoparticles for docetaxel delivery to drug-resistant cancer cells,” Int. J. Nanomedicine, vol. 10, pp. 5249–5262, 2015, doi: 10.2147/IJN.S89584.

M. T. Vu, N. T. T. Le, T. L. B. Pham, N. H. Nguyen, and D. H. Nguyen, “Development and Characterization of Soy Lecithin Liposome as Potential Drug Carrier Systems for Codelivery of Letrozole and Paclitaxel,” J. Nanomater., vol. 2020, 2020, doi: 10.1155/2020/8896455.

T. K. Shaw et al., “Successful delivery of docetaxel to rat brain using experimentally developed nanoliposome : a treatment strategy for brain tumor Successful delivery of docetaxel to rat brain using experimentally developed nanoliposome : a treatment strategy for brain tum,” vol. 7544, 2017, doi: 10.1080/10717544.2016.1253798.